Envarsus XR
Total Payments
$1.5M
Transactions
1,297
Doctors
513
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $952,493 | 23 | 0 |
| 2017 | $537,805 | 1,274 | 513 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 29 | 74.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $276,350 | 126 | 18.5% |
| Travel and Lodging | $61,687 | 161 | 4.1% |
| Food and Beverage | $41,024 | 826 | 2.8% |
| Education | $1,912 | 155 | 0.1% |
Payments by Type
Research
$1.1M
29 transactions
General
$380,973
1,268 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II, single-center, Open-label study to evaluate the comparable efficacy of Tacrolimus extended release tablets Envarsus r to the standard of care SOC twice daily tacrolimus Prograf r dosing regimen | Veloxis Pharmaceuticals, Inc. | $131,512 | 0 |
| Once-daily extended-release tacrolimus vs. twice-daily tacrolimus. Impact on T-cell subpopulations and markers of renal tubule-toxicity in kidney transplant patients | Veloxis Pharmaceuticals, Inc. | $126,883 | 0 |
| CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $125,124 | 0 |
| A Prospective, Randomized, Single-center, Pilot Study of Envarsus XR to Examine Safety, Medication Adherence, and Patient Reported Outcomes in Adolescent Renal Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $88,949 | 0 |
| Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus | Veloxis Pharmaceuticals, Inc. | $83,779 | 0 |
| Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants PTAAK | Veloxis Pharmaceuticals, Inc. | $73,006 | 0 |
| Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $71,400 | 0 |
| Impact of Envarsus XR (r) on kidney biopsy subclinical rejection and blood immunologic profile | Veloxis Pharmaceuticals, Inc. | $61,838 | 0 |
| Role for Envarsus in Renal Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $59,200 | 0 |
| Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function eGFR in Kidney Transplantation | Veloxis Pharmaceuticals, Inc. | $42,723 | 0 |
| Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus LCPT in Kidney Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $41,322 | 0 |
| A Pilot Study to Evaluate Impact on Neurological Side Effects Cognition, Memory, and Tremor in Elderly Age greater than 65 Patients | Veloxis Pharmaceuticals, Inc. | $33,075 | 0 |
| Clinical outcomes of LCP-Tacrolimus Envarsus, Once Daily Versus Tacrolimus IR Twice Daily in De Novo Kidney Transplant Recipients in the U.S. | Veloxis Pharmaceuticals, Inc. | $32,082 | 0 |
| A pilot study of stable kidney transplant recipients taking tacrolimus with CNS symptoms switched to Envarsus | Veloxis Pharmaceuticals, Inc. | $24,068 | 0 |
| Phase II, single-center, Open-label study to evaluate the comparable efficacy of Tacrolimus extended release tablets (Envarsus(r)) to the standard of care (SOC) twice daily tacrolimus (Prograf(r)) dosing regimen | Veloxis Pharmaceuticals, Inc. | $21,919 | 0 |
| An Evaluation of Converting Elderly Kidney Transplant Recipients from Tacrolimus to Envarsus to Limit Neurological Adverse Events and Improve Quality of Life | Veloxis Pharmaceuticals, Inc. | $21,875 | 0 |
| Assessment of cognitive function before and after conversion from immediate release tacrolimus to Envarsus XR | Veloxis Pharmaceuticals, Inc. | $20,558 | 0 |
| A Randomized Pilot Study of Treatment for Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $14,441 | 0 |
| A randomized controlled trial to evaluate the clinical benefit of EnvarsusXR in post liver transplant patients | Veloxis Pharmaceuticals, Inc. | $12,000 | 0 |
| Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant | Veloxis Pharmaceuticals, Inc. | $12,000 | 0 |
Top Doctors Receiving Payments for Envarsus XR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $1.1M | 29 |
| , MD | Nephrology | Saint Louis, MO | $60,538 | 50 |
| , M.D | Transplant Surgery | Tyler, TX | $26,960 | 31 |
| , M.D | Nephrology | Los Angeles, CA | $26,599 | 27 |
| , M.D | Transplant Surgery | Washington, DC | $26,141 | 29 |
| , MD | Transplant Surgery | Saint Louis, MO | $25,505 | 28 |
| , M.D | Transplant Surgery | Oak Lawn, IL | $24,805 | 32 |
| , MD | Nephrology | Baltimore, MD | $16,738 | 19 |
| , MD | Nephrology | Salt Lake City, UT | $14,890 | 22 |
| , MD | Transplant Surgery | Nashville, TN | $14,242 | 22 |
| , M.D | Nephrology | Los Angeles, CA | $11,541 | 10 |
| , M.D.,PH.D | Surgery | Harrisburg, PA | $10,374 | 16 |
| , MD | Nephrology | Providence, RI | $10,326 | 9 |
| , MD | Nephrology | Loma Linda, CA | $10,217 | 18 |
| , MD | Nephrology | Ewa Beach, HI | $7,878 | 7 |
| , MD | Nephrology | San Francisco, CA | $6,121 | 10 |
| , M.D | Nephrology | Shreveport, LA | $5,777 | 6 |
| , M.D., PHD | Surgery | San Diego, CA | $5,770 | 8 |
| , M.D | Transplant Surgery | New York, NY | $4,411 | 10 |
| , M.D | Nephrology | Boston, MA | $4,386 | 11 |
| , MD | Transplant Surgery | Memphis, TN | $4,376 | 13 |
| , M.D | Urology | Stony Brook, NY | $4,368 | 19 |
| , MD | Nephrology | Charleston, SC | $4,292 | 11 |
| , MD | Nephrology | Cleveland, OH | $4,291 | 12 |
| , MD | Nephrology | Merion Station, PA | $4,196 | 8 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 513
- Transactions 1,297
About Envarsus XR
Envarsus XR is a drug associated with $1.5M in payments to 513 healthcare providers, recorded across 1,297 transactions in the CMS Open Payments database. The primary manufacturer is Veloxis Pharmaceuticals, Inc..
Payment data is available from 2017 to 2018. In 2018, $952,493 was paid across 23 transactions to 0 doctors.
The most common payment nature for Envarsus XR is "Unspecified" ($1.1M, 74.4% of total).
Envarsus XR is associated with 20 research studies, including "Phase II, single-center, Open-label study to evaluate the comparable efficacy of Tacrolimus extended release tablets Envarsus r to the standard of care SOC twice daily tacrolimus Prograf r dosing regimen" ($131,512).